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Abstract
We used neuronal nitric oxide synthase (nNOS) gene knockout mice to study the effects of
catecholamines and neuronal nitric oxide on vasopressin expression in the hypothalamic
neurosecretory centers. nNOS gene deletion did not change the level of vasopressin mRNA in the
supraoptic or paraventricular nuclei. In contrast, vasopressin immunoreactivity was lower in nNOS
deficient mice than in wild-type animals. Dehydration increased vasopressin mRNA levels and
decreased vasopressin immunoreactivity in both wild-type and nNOS knockout mice, but these
responses were more marked in the nNOS knockout mice. Treatment with ?-mpt, a pharmacologic
inhibitor of catecholamine synthesis, resulted in increased vasopressin mRNA levels in wild-type
mice and in reduced vasopressin immunoreactivity in both wild-type and nNOS knockout mice. From
these results, we conclude: (1) neuronal nitric oxide suppresses vasopressin expression under basal
conditions and during activation of the vasopressin-ergic system by dehydration; (2) catecholamines
limit vasopressin expression; (3) nNOS is required for the effects of catecholamines on vasopressin
expression.
It is well known that vasopressin (VP) plays a major role in the regulation of body water and
osmolality (1). VP is primarily synthesized by magnocellular neurons in the paraventricular
(PVN) and supraoptic (SON) nuclei of the hypothalamus. It is then transported down the axons
to the posterior neurohypophysis, where it is released into the systemic circulation. The
biosynthesis and release of VP is regulated by plasma osmotic pressure and blood pressure or
blood volume (2). Catecholamines influence VP synthesis and release by mechanisms that are
still not fully understood. Catecholaminergic neurons make synaptic contacts with VP-ergic
neurons in the hypothalamus (3) and all three types of adrenoreceptors (?1, ?2, ?) are found
on SON and PVN neurons (4). Catecholamines have been reported both to activate and inhibit
VP synthesis and release (5,6). Nitric oxide (NO) has also been reported to modulate VP
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synthesis and release, both in a stimulatory and an inhibitory manner (7). Based on this
published data, we hypothesize that NO and catecholamines can both modulate VP expression,
especially when VP synthesis is upregulated by dehydration. In this paper, we study the
interaction between catecholamines and neuronal NO in VP synthesis and expression, using
neuronal nitric oxide synthase (nNOS) gene knockout mice.
All procedures were approved by the Institutional Animal Care and Use Committee at
Massachusetts General Hospital. WT (C57BL/6J) mice (Jackson Labs) and nNOS knockout
mice lacking exon 2 (8) were housed under diurnal lighting conditions and allowed food and
water ad libitum. We used 20 adult male WT and 20 nNOS knockout mice, 10-12 weeks of
age, body weight 20-30 g. WT and nNOS knockout mice were divided into four groups of five
animals. Mice in the first group (controls) had free access to food and water. Mice in the second
group were deprived of water for 5 days. Mice in the third group received daily intraperitoneal
injections of ?-mpt, a blocker of catecholamine synthesis (9), for five days at a dose of 100
mg/kg body weight. Mice in the fourth group were deprived of water for five days, and received
daily intraperitoneal injections of ?-mpt.
The hypothalamic areas were dissected, fixed in 4% paraformaldehyde overnight at 4°C and
embedded in paraffin. Paraffin tissue blocks were cut into 8?m-thick frontal sections for in
situ hybridization and 5 ?m-thick frontal sections for immunohistochemistry. The sections
containing the SON and PVN, and zona inserta (ZI) were sequentially processed for the in situ
hybridization and immunostaining procedures.
The VP probe was generated from a 229-bp Dra/Pst cDNA fragment. It binds to the 3?-end of
the VP mRNA. This fragment was inserted into a pGEM1 vector (gift of Prof. H. Gainer,
NINDS, NIH). The plasmid was linearized by HindIII and used as template for synthesis of
antisense mRNA probe. Digoxigenin-labeled probe was prepared from VP cDNA templates
using digoxigenin-UTP (Boehinger Mannheim). Hybridization was performed with
digoxigenin-labeled VP riboprobes using standard protocols as previously described (10).
To visualize digoxigenin-staining, sections were rinsed twice in buffer 1 (100 mM Tris-HCl/
150 mM NaCl, pH 7.5) for 10 min, followed by 30 min incubation in modified blocking solution
(buffer 1 containing 0.5 % bovine serum albumin and 1 % blocking reagent, Boehringer
Mannheim). They were then incubated overnight with alkaline phosphatase-conjugated anti-
digoxigenin antiserum (Boehringer Mannheim; 1:500 in modified blocking solution). Sections
were consecutively rinsed twice in buffer 1 for 15 min, and in buffer 2 (100 mM Tris-HCl/100
mM NaCl/10 mM MgCl2, pH9.5) for 3 min. Finally, sections were incubated overnight at RT
in the dark in buffer 2 containing 0.34 mg/ml nitroblue tetrazolium salt and 0.18 mg/ml 5-
bromo-4-chloro-3indolyl phosphate toluidinium salt (NBT/BCIP; Boehringer Mannheim),
rinsed in buffer 3 (100 mM Tris-HCl/1 mM EDTA) and coverslipped with carbonate buffered
glycerol (0.5 M carbonate buffer, pH 8.6/50 % glycerol).
After deparaffinization and rehydration, slides containing 5 ?m-thick frontal sections of
hypothalamic region were incubated in peroxidase blocking solution (3% H2O2 in PBS) for
15 min. Staining of experimental and control slides was performed simultaneously in the same
solutions. The peroxidase-antiperoxidase complex (PAP) method was used for VP (1:100) and
tyrosine hydroxylase (TH, 1:500) immunostaining. After peroxidase blocking, the slides were
rinsed in PBS, incubated in 10% sucrose in PBS, washed in PBS and placed in blocking buffer
(2% normal goat serum in PBS) for 1 hour. The sections were incubated successively with:
primary rabbit antibody against VP or TH overnight; goat anti-rabbit IgG (1:100) for 1 h; and
PAP complex (1:100) for 1 hour. Finally, the sections (without additional counterstaining)
were dehydrated and mounted with coverslips. All immunohistochemical reactions were
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carried out in parallel with reactions lacking primary antibody to ensure the specificity of the
observed staining.
Digoxigenin-labeled VP-mRNA level and VP-immunoreactivity in neurosecretory cells were
quantified by optical density measurements using a digital video analysis system (VideoTest)
(11). 5-6 slices of SON and the magnocellular part of PVN were analyzed from each mouse.
The number of mice in each experimental group was five. VP- immunoreactivity was measured
at 550 nm. Optical density of digoxigenin-labeled VP-mRNA was estimated at 650 nm in
adjacent slices. Optical density was calculated as gray level of immunoreactive brain tissue
field minus background grey level. Optical density of background was estimated using a non-
immunoreactive brain tissue field in the same section. The results are presented in relative units
of optical density at ?m2. Measurement of VP mRNA in hypothalamic neurons reflects VP
synthesis. This data, taken together with VP-immunoreactivity (VP content) allows us to
estimate VP release.
The data are expressed as the mean ± SEM. t-test was used to determine significance among
groups. A value of P<0.05 was considered to be statistically significant.
In this paper, we study the interaction between NO and catecholamines, and the involvement
of this crosstalk in the regulation of VP expression. nNOS knockout mice are useful tools to
define the roles of neuronal NO under stress conditions like water deprivation or depressed
catecholamine innervation. While there are pharmacologic inhibitors of nNOS, they are not
absolutely specific and have been shown to inhibit the other NOS isoforms (12). In the current
study, we used nNOS knockout mice to determine whether long-term NO deficiency would
affect VP expression, and how this condition would modulate the effects of dehydration or ?-
mpt. nNOS knockout mice show normal arterial blood pressure and renal blood flow compared
with WT mice (13). Importantly, expression of neurophysin, the carrier protein of vasopressin/
oxytocin, is not altered (14).
We found that nNOS gene deletion did not change the optical density of labeled VP mRNA in
the SON or PVN (Fig. 1A, 2A). In contrast, VP immunoreactivity was lower in nNOS deficient
mice than in WT animals (Fig. 1B, 2B). There is substantial evidence that NO is involved in
the regulation of VP synthesis and release (15). Dehydration increases NO synthase activity
in the hypothalamus and pituitary (16,17). nNOS expression in the SON and PVN is
upregulated by non-osmotic hypovolemia (17). Blockade of NO synthesis increases
vasopressin secretion (7). We believe that increased VP mRNA levels and decreased VP
immunoreactivity are consistent with increased release of VP from the cell bodies. This claim
and methodology is validated by publications in the literature demonstrating that increased
mRNA levels for VP, oxytocin and some other hypothalamic neuropeptides indicates increased
synthesis. Furthermore, decreased immunoreactivity in the cell bodies suggests increased
release into the hypophyseal portal system (10,18-21).
Our results suggest that NO plays a role in suppressing the release of VP. This may occur not
only from axonal terminals in the neurohypophysis, but also from neuronal cell bodies.
Decreased immunoreactivity and increased mRNA level might be represent enhanced release,
decreased translation or increased protein degradation. Further studies with measurement of
plasma VP levels need to be done to clarify effects on VP release.
To assess the effect of dehydration or ?-mpt on VP mRNA contents, we measured optical
density of digoxigenin-labeled VP mRNA in SON of WT and nNOS knockout mice. As seen
in Figure 1A, in the SON of WT animals, blockade of catecholamine synthesis with ?-mpt,
dehydration with ?-mpt treatment and dehydration (Fig. 1A, 3A, 3B), all increase VP mRNA
expression compared with control animals. In nNOS knockout mice, dehydration increased
VP mRNA synthesis (Figure 1A, 3C, 3D), but ?-mpt treatment did not (Figure 1A).
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Administration of ?-mpt to nNOS knockout mice during dehydration caused a decrease in VP
mRNA level as compared with dehydration alone, but the level was still significantly higher
than in untreated nNOS knockout mice (Figure 1A).
In WT mice, treatment with ?-mpt, dehydration, and treatment with ?-mpt with dehydration
all increase VP mRNA levels in PVN (Figure 1A and 2A). Treatment with ?-mpt caused some
increase in VP mRNA level in nNOS knockout mice, but less than that seen in WT mice. In
contrast, dehydration caused a significantly higher increase in VP mRNA in nNOS knockout
mice than in WT mice. Finally, ?-mpt treatment of dehydrated nNOS knockout mice caused
a decrease in VP mRNA level as compared with dehydration alone.
We also measured VP immunoreactivity in the SON and PVN of WT and nNOS knockout
mice (Figure 1B, 2B). In WT mice, blockade of catecholamines synthesis with ?-mpt (Figure
1B, 2B), dehydration (Figure 1B, 2B, 4A, 4B), and dehydration with ?-mpt treatment (Figure
1B, 2B) all moderately reduce VP immunoreactivity. nNOS knockout mice showed less
immunoreactive VP in the SON and PVN than in WT mice under control conditions and in all
experimental groups. Dehydration caused a marked decrease in VP immunoreactivity in nNOS
knockout mice (Figure 1B, 2 B, 4C, 4D). Treatment with ?-mpt also reduced VP
immunoreactivity, but to a lesser extent (Figure 1B, 2B). Finally, the combination of ?-mpt
treatment and dehydration did not lower VP immunoreactivity any further in nNOS knockout
mice (Figure 1B, 2B).
The role of NO in VP content is controversial. NO has been shown both to stimulate or to
inhibit VP release (22). Central inhibition of NOS with L-NAME showed decrease in plasma
level of VP (23). Our data directly confirm that neuronal NO modulates the VP response to
osmotic stimulation. Dehydration increases VP mRNA levels in the PVN and SON of both
WT and nNOS knockout mice. This response is more marked in nNOS knockout mice,
suggesting that nNOS normally blunts the response to dehydration.
In addition to VP synthesis, NO also appears to play a role in VP release, both under basal
conditions, and with dehydration. The decrease in VP immunoreactivity with dehydration,
reflecting VP release from nerve terminals, was more marked in nNOS knockout mice. Based
on published data (18-21), we interpret the decreased immunoreactivity as a reflection of
increased secretion level of VP form the cell bodies. This suggests that nNOS-derived NO
blunts the release of VP. In its absence, VP release occurs more readily.
To identify expression of catecholamines, we measured TH immunoreactivity in ZI in WT and
nNOS knockout mice. The ZI mainly contains dopaminergic neurons, and is one of the main
regions that innervates PVN with dopamine (24). Our results demonstrate that nNOS
deficiency led to significant decrease of catecholamines content in the cell bodies (Fig. 5).
We used ?-mpt to block catecholamine synthesis. Under the conditions we used, ?-mpt reduces
catecholamines levels to 14% of control levels (9). Treatment with ?-mpt resulted in increased
VP mRNA (greater synthesis) levels in SON and PVN of WT mice (Fig. 1A,2A). However
the effect was absent or markedly blunted in nNOS knockout mice, where synthesis of
catecholamines was significantly diminished (Fig. 5). These results suggest that nNOS is
required for the effects of catecholamines synthesis blockade. In this regard, hypothalamic
nNOS expression is increased by ?-mpt in rats (25). On the other hand, CA modulates VP
release from hypothalamo-hypophyseal system (5,6). Therefore, the lack of effect of CA in
nNOS knockout mice indicates that catecholamine acts through NOS to modulate VP
production. nNOS is main isoform modulating catecholamine secretion and release (26,27).
eNOS can also modulate cathecholamine secretion and release (27,28), but there is as yet no
evidence for a role for iNOS in catecholamine regulation.
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We demonstrated that ?-mpt treatment reduces VP immunoreactivity in both WT and nNOS
knockout mice in PVN and SON neurons. These results suggest that catecholamine synthesis
tonically blunts VP release, so that when catecholamine synthesis is blocked by ?-mpt, there
is more VP release.
In WT mice, dehydration and ?-mpt treatment reduce VP immunoreactivity in the SON more
than dehydration alone. However, VP mRNA levels were comparable in these two groups. We
conclude that catecholamine depression enhances the effects of water deprivation on VP
release. This suggests that catecholamines may limit VP release, even under conditions of
dehydration, a possible protective mechanism to prevent depletion of VP under conditions that
stimulate release.
Dehydration increases VP mRNA levels. Decreased VP immunoreactivity was more marked
in nNOS knockout mice. Simultaneous treatment with ?-mpt did not change VP protein or
mRNA content in nNOS knockout animals, confirming a role for nNOS as a dominant regulator
of the effects of water deprivation.
In conclusion, we show that deletion of the nNOS gene is associated with decreased VP protein
content in the hypothalamic neurons, suggesting increased release of VP from cell bodies.
Neuronal nitric oxide suppresses VP release under basal conditions and during activation of
the VP-ergic system by dehydration. Inhibition of catecholamine synthesis results in enhanced
VP release, suggesting that catecholamines limit VP release under basal and osmotic
stimulation conditions. nNOS is required for the effects of catecholamines on VP synthesis.
Thus, nNOS plays important roles in basal VP release, VP responses to dehydration, and the
effects of catecholamines on VP synthesis.
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?-mpt treatment, dehydration, and ?-mpt treatment during dehydration increase VP mRNA
content and diminish VP immunoreactivity in VP magnocellular neurons of hypothalamic
SON. A. The content of VP RNA; B. VP-immunoreactivity in the SON in WT (white columns)
and nNOS knockout mice (black columns). X axis: control – intact mice; ?-mpt – injection of
catecholamine synthesis blockator ?-mpt (100 mg/kg); DH –dehydrated mice; DH+?-mpt -
?-mpt injection (100 mg/kg) during dehydration.
Y axis: optical density (conventional units/?m2)
* - p<0.05 compared to control;
**- p<0.05 compared to control and *;
#- p<0.05 as compared with WT mice.
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Effects of ?-mpt treatment, dehydration, and ?-mpt treatment during dehydration on VP
expression in PVN of hypothalamus. A. The content of VP RNA; B. VP-immunoreactivity in
the PVN in WT (white columns) and nNOS knockout mice (black columns).
X and Y axes, *, **, # are same as that for Figure 1.
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In situ hybridization of VP mRNA with digoxigenin-labeled antisense VP-RNA probe in the
SON of nNOS deficient and WT mice. A, C – digoxigenin-positive VP mRNA in control group
of WT and nNOS knockout mice respectively; and in dehydrated animals: B – WT mice, D –
nNOS knockout mice. Hybridization with sense VP-RNA probe was negative (not shown).
Arrows indicate localization of the SON. OT is optical tract. Scale bar is 100 ?m.
Liubov et al. Page 10























Effect of dehydration on functional activity of VP-ergic cells in the SON. Cytoplasmic stain
of VP in neurons of the SON in control WT (A) and nNOS knockout mice (C); and dehydrated
animals: B – WT, and D – nNOS knockout mice. Arrows indicate location of SON. Detection
of VP was performed without additional counterstaining. OT is optical tract.
Scale bar is 100 ?m.
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nNOS deficiency leads to decrease of TH protein content in ZI of mouse hypothalamus. Data
for optical density is presented as arbitrary units per ?m2.
Axis X: WT (white columns) – intact WT mice; nNOS-/- (black columns) – nNOS knockout
intact mice.
* - p<0.05 compared to WT mice.
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